Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Accumulated Expenses (2019 - 2025)

Biodesix's Accumulated Expenses history spans 7 years, with the latest figure at $767000.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 16.54% year-over-year to $767000.0; the TTM value through Dec 2025 reached $767000.0, down 16.54%, while the annual FY2025 figure was $767000.0, 16.54% down from the prior year.
  • Accumulated Expenses reached $767000.0 in Q4 2025 per BDSX's latest filing, down from $9.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $9.7 million in Q3 2025 to a low of $767000.0 in Q4 2025.
  • Average Accumulated Expenses over 5 years is $3.7 million, with a median of $3.9 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: surged 542.78% in 2023, then crashed 82.72% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $4.0 million in 2021, then rose by 15.93% to $4.7 million in 2022, then dropped by 17.47% to $3.9 million in 2023, then plummeted by 76.16% to $919000.0 in 2024, then decreased by 16.54% to $767000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Accumulated Expenses are $767000.0 (Q4 2025), $9.7 million (Q3 2025), and $803000.0 (Q2 2025).